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an estimated calculation of costs-to-charges from the Medicare
Cost Report. Regression modeling with log transformation was
employed to compare differences in ﬁxed hospital costs (those
insensitive to volume), variable costs (those sensitive to volume),
and post-operative LOS. Control variables included age, gender,
All Patient Reﬁned-Diagnosis Related Group severity codes,
region, hospital teaching status, bed size, population served
(urban or rural), and primary payer. RESULTS: A total of 82,788
discharges were included. The models demonstrated that patients
who received Gelfoam + thrombin had higher ﬁxed and variable
costs (+6.1% and +7.3%, respectively, p < 0.01) and Surgicel +
thrombin patients had higher ﬁxed and variable costs (+18% and
+10%, p < 0.01, respectively) compared to FloSeal only. In terms
of ﬁxed costs, the predicted increase was $15,956 for Gelfoam +
thrombin and $18,639 for Surgicel + thrombin patients. In
terms of variable costs, the predicted increase was $25,413
per Gelfoam + thrombin and $24,909 per Surgicel + thrombin
patient. Surgicel+ thrombin patients also had higher (+6%,
p < 0.01) post-operative LOS compared to FloSeal patients.
CONCLUSION: FloSeal demonstrated signiﬁcant cost reductions
and post-operative LOS, compared to other commonly-used
products. Limited prospective reimbursements based on a DRG
system make it necessary for health care providers to consider
more cost-effective surgical aids for spinal surgeries.
PHC3
COST-EFFECTIVENESS MODELING OF DENTAL IMPLANT 1ST
LINE STRATEGYVERSUS BRIDGE
Beresniak A1, Bouchard P2, Renouard F3, Bourgeois D4,
Jeanneret MH5
1Data Mining International, Geneva, Switzerland, 2University Denis
Diderot, Paris, France, 3Centre d’Implantologie, Paris, France,
4University Lyon 1,Villeurbanne, France, 5University Paris-Descartes,
Paris, French Guiana
OBJECTIVE: We assessed the cost-effectiveness of dental
implant 1st line strategy versus ﬁxed partial denture (and
denture) in patients suffering from one single missing tooth.
METHODS: The model used a simulation decision framework
over a 20-year period. Potential treatment switches can occur
every 5 years. Transition probabilities came from literature,
epidemiological reports or expert opinions. They have been
programmed using speciﬁc distribution ranges to simulate the
patients and practice variability, and to take into account param-
eters uncertainty. Direct medical costs have been assessed accord-
ing to a speciﬁc cost survey in France. Probabilistic sensitivity
analyses were conducted using 5000 Monte-Carlo simulations
generating conﬁdence intervals of model outcomes. RESULTS:
The cost distribution indicates a peak at €3000 for the bridge
strategy. The distribution for the implant strategy is more ﬂat,
showing the maximum ranging from €2500 to €3500. The model
simulations establish that total mean cost of the bridge 1st line
strategy is €4385 per patient over 20 years (minimum: €1850;
maximum: €17,267), providing 69% of success rate. Total mean
cost of the implant 1st line strategy is €3517 per patient over 20
years (minimum: €1990 Euros; maximum: €10,221 Euros), with
92% of success rate. Differences are statistically signiﬁcant for
both total mean costs (p < 0.001) and success rate (p < 0.001).
The mean cost-effectiveness (cost per functional dental unit in
position) is shown in Figure 3c. It indicates that the bridge
strategy is signiﬁcantly higher (p < 0.001) than the implant strat-
egy with €6286/success versus 3819 Euros/success respectively.
CONCLUSION: This simulation modeling approach is the very
ﬁrst robust model in the ﬁeld of implantology. Implant as the 1st
line strategy appears to be the “dominant” strategy, considering
the lower overall costs and the higher success rate.
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OBJECTIVE: For 20 years, thromboprophylactic strategies (TSs)
have been used after total hip replacement (THR). Our objective
was to conduct a comprehensive cost effectiveness analysis (CEA)
of TSs for THR from the health payer perspective. METHODS:
We extracted national data for Veteran patients receiving THR,
including 1-year follow-up of all heath care utilization and
complications of venous thromboembolic events (VTE: deep vein
thrombosis, pulmonary embolism), thombocytopenia, bleeding,
and death. Diagnostic codes were used to identify most compli-
cations. A comparative CE model, incorporating fondaparinux,
was developed. Incremental cost-effectiveness ratios (ICERs)
were calculated to compare TSs. Life-years gained (LYG) were
calculated using actuarial tables for life expectancy. Since fonda-
parinux was rarely used in the VA, we applied rates from pub-
lished trials and used our data to estimate proportional increases
in complication rates for fondaparinux from day 50 through one
year. We applied VA costs. Fondaparinux costs were based upon
mean costs of outcomes of the other TSs. One-way sensitivity
analyses (SA) were performed by incorporating the mean prob-
abilities of DVT in the other TSs into the least-costly TS or
decreasing the costs of complication arms by one standard devia-
tion in all but the least-costly TS. RESULTS: There were 1722
patients, 90 VTEs, and 48 deaths. Dalteparin was dominant;
the least-costly per patient with fewest VTEs ($18,850, 2.4%)
compared to warfarin ($18,953, 6.4%), enoxaparin ($19,965,
2.7%), enoxaparin/warfarin ($24,809, 21.6%), and fonda-
parinux ($20,759, 5.2%). Thus, ICERS indicated more costs and
more events with other TSs. Deaths occurred in 2.4% of dalte-
parin patients versus 2.3% for enoxaparin and, estimated, 1.0%,
for fondaparinux, thus ICERS for LYG were $35,754/LYG and
$6381/LYG, respectively. Dalteparin and other treatments were
dominant over warfarin (2.9% deaths) and enoxaparin/warfarin
(6.0% deaths)for LYG. Each SA showed dalteparin remained the
least-costly TS per VTE avoided. CONCLUSION: Dalteparin
was slightly more effective and less costly.
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OBJECTIVE: There is a lack of cost effectiveness (CE) analyses
of thromboprophylactic strategies (TSs) for total knee replace-
ment (TKR) that incorporate outpatient care, long-term follow-
up, or complications besides venothrombotic events (VTE: deep
vein thrombosis, pulmonary embolism). The objective was to
assess the CE of TSs for TKR from the health payer perspective
including complications of VTE, hemorrhage, thrombocyto-
penia, and death. METHODS: We searched national Veterans
Affairs (VA) datasets for all health care use, outcomes and VA
costs for patients receiving TKR within one year. Our follow-up
was one year. Diagnostic codes were used to identify complica-
tions. Life-years gained (LYG) were calculated using actuarial
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tables. A comparative CE model, incorporating fondaparinux,
was developed. Incremental cost-effectiveness ratios (ICERs)
were calculated. Since no fondaparinux was used, we applied
rates from published trials, and adjusted for the mean propor-
tional increase in rates between 49 days (trial follow-up) and
one year in Veterans. For fondaparinux, costs were estimated
from mean costs of complications among the other TSs, with an
adjustment for increased medication cost. One-way sensitivity
analyses (SA) were performed by incorporating the mean prob-
abilities of DVT among each other TSs into the least-costly TS
or decreasing the costs of complication arms by one standard
deviation. RESULTS: There were 3037 patients, 131 VTEs, and
53 deaths. Dalteparin was dominant; the least-costly per patient
with fewest VTEs ($16,310, 1.0%) compared to warfarin
($17,803, 3.5%), enoxaparin ($19,253, 2.4%), enoxaparin/
warfarin ($23,641, 22.7%), and fondaparinux ($19,577, 1.6%).
Thus, ICERS indicated more costs and more events with other
TSs. Deaths occurred in 2% of dalteparin patients, thus ICERS
for LYG (deaths) were warfarin $27,004 (1.7%), enoxaparin
$33,232 (1.5%), enoxaparin/warfarin $40,479 (1.1%), and
fondaparinux $20,355 (estimated 1.2%). Each SA showed dalte-
parin remained the least-costly TS per VTE avoided. CONCLU-
SION: Dalteparin was the least-costly TS and had the fewest
VTEs.
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OBJECTIVE: The objective of this study was to compare the
cost-effectiveness of tension-free mesh and tension suture
methods of inguinal hernia repair in Hungary, from hospital and
payer perspectives. METHODS: Cost effectiveness of open mesh
vs. open non mesh was modeled with a Cohort Markov model.
Model simulation runs in yearly cycles up to 15 years. Transition
probabilities were derived from systematic review and other pub-
lished sources. Costs were collected from two hospitals and from
the payer in Hungary. Utility values were extracted from the
published sources. Both costs and outcomes were discounted
annually at 5%. In probabilistic sensitive analysis simulations
were repeated 10,000 times. CEAC curves were generated as a
result of simulation for all scenarios. RESULTS: Over a 5 and 15
year period open mesh provides greater beneﬁts in terms of more
QALYs and fewer recurrences at a cumulatively higher cost than
open non mesh procedures. Cost per one additional QALY is
€13,221 in a 5 years time horizon and €2819 in a 15 years time
horizon from a payer perspective. Cost per one recurrence
avoided is €885 in a 5 years time horizon and €173 in a 15 years
time horizon from payer perspective. When the costs from a
hospital perspective are used the open mesh option is the domi-
nant technology over the open non mesh option. Results in the
probability sensitivity analysis are very similar to deterministic
analysis. In the ﬁve year perspective open mesh is the more cost
effective option in comparison to open non mesh option when
the value for society’s willingness to pay for a QALY exceeds
€6000 (€700 in the 15 years perspective). CONCLUSION: Find-
ings suggest open mesh hernia repair method as a very cost
effective therapy from both hospitals and payer perspectives for
the inguinal hernia treatment in Hungary.
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OBJECTIVE: To compare the cost-effectiveness of tension-free
mesh and tension suture methods of inguinal hernia repair in
Poland, from hospital and payer perspectives. METHODS: Cost
effectiveness of open mesh vs open non mesh was modeled with
a Cohort Markov model. Model simulation runs in yearly cycles
up to 15 years. Transition probabilities were derived from sys-
tematic review and other published sources. Costs were collected
from four hospitals and from the payer in Poland. Utility values
were extracted from the published sources. Both costs and out-
comes were discounted annually at 5%. In probabilistic sensitive
analysis simulations were repeated 10,000 times. CEAC curves
were generated as a result of simulation for all scenarios.
RESULTS: Over a 5 and 15 year period open mesh provides
greater beneﬁts in terms of more QALYs and fewer recurrences at
a cumulatively higher cost than open non mesh. The cost per one
additional QALY is €16,730 in a 5 years time horizon and €3236
in a 15 years time horizon from a payer perspective (€16,485 and
€3061 respectively from a hospital perspective). Cost per one
recurrence avoided is €1096 in a 5 years time horizon and €199
in a ﬁfteen years time horizon from a payer perspective (€1103
and €188 respectively from hospital perspective). Results from
the probability sensitivity analysis are very similar to determin-
istic analyses. In the ﬁve year perspective open mesh is more
cost effective in comparison to the open non mesh option when
the value for society’s willingness to pay for a QALY exceeds
€10,000 (€500 in the 15 years perspective). CONCLUSION:
Findings suggest open mesh hernia repair method as a very cost
effective therapy from both hospitals and payer perspectives for
the inguinal hernia treatment in Poland.
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OBJECTIVE: The objective of this study was to compare the
cost-effectiveness of tension-free mesh and tension suture
methods of inguinal hernia repair in Slovakia, from hospital and
the payer perspective. METHODS: Cost effectiveness of open
mesh vs open non mesh was modeled with a Cohort Markov
model. Model simulation runs in yearly cycles up to 15 years.
Transition probabilities were derived from systematic review and
other published sources. Costs were collected from two hospitals
and from the payer in Slovakia. Utility values were extracted
from the published sources. Both costs and outcomes were dis-
counted annually at 5%. In probabilistic sensitive analysis simu-
lations were repeated 10,000 times. CEAC curves were generated
as a result of simulation for all scenarios. RESULTS: Over a 5
and 15 year period open mesh provides greater beneﬁts in terms
of more QALYs and fewer recurrences than open non-mesh.
When the costs from a payer’s perspective are used the open
mesh option is the dominant technology over open non mesh
option (equal payment for open mesh and open non mesh
options). The cost per one additional QALY is €1230 in a 5 years
time horizon and the open mesh is the cost effective option in a
15 years time horizon from a hospital perspective. Cost per one
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